{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:13:21Z","timestamp":1794305601965,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this multicentered phase II trial (NCT04303741), 46 patients with pretreated advanced TNBC were enrolled to receive camrelizumab 200\u2009mg (day 1), and apatinib 250\u2009mg daily, plus eribulin 1.4\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    (day 1 and 8) on a 21-day cycle until progression, or unacceptable toxicity. Primary endpoint was objective response rate (ORR) according to RECIST 1.1. Secondary endpoints included toxicities, disease control rate (DCR), clinical benefit rate, progression-free survival (PFS), and 1-year overall survival. With a median of 3 lines of prior chemotherapy in the advanced setting, 17.4% had received PD-1\/PD-L1 blockade plus chemotherapy for advanced disease. The ORR was 37.0% (17\/46, 95% CI 23.2\u201352.5). The DCR was 87.0% (40\/46, 95% CI 73.7\u201395.1). Median PFS was 8.1 (95% CI 4.6\u201310.3) months. Tertiary lymphoid structure was associated with higher ORR. Patients with lower tumor PML or PLOD3 expression had favorable ORR and PFS. PD-L1 status was not associated with ORR\/PFS. Grade 3\/4 treatment-related adverse events occurred in 19 (41.3%) of 46 patients. Camrelizumab plus apatinib and eribulin shows promising efficacy with a measurable safety profile in patients with heavily pretreated advanced TNBC.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-30569-0","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T06:03:42Z","timestamp":1653977022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"Jieqiong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenluan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-2224","authenticated-orcid":false,"given":"Hengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-4862","authenticated-orcid":false,"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-3587","authenticated-orcid":false,"given":"Shicheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinduo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-6469","authenticated-orcid":false,"given":"Herui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-633X","authenticated-orcid":false,"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-9049","authenticated-orcid":false,"given":"Erwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"30569_CR1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","volume":"19","author":"M Bonotto","year":"2014","unstructured":"Bonotto, M. et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19, 608\u2013615 (2014).","journal-title":"Oncologist"},{"key":"30569_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1210-4","volume":"21","author":"CH Li","year":"2019","unstructured":"Li, C. H., Karantza, V., Aktan, G. & Lala, M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res 21, 143 (2019).","journal-title":"Breast Cancer Res"},{"key":"30569_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44\u201359 (2020).","journal-title":"Lancet Oncol."},{"key":"30569_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"30569_CR5","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","volume":"27","author":"SM Tolaney","year":"2021","unstructured":"Tolaney, S. M. et al. Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): A phase Ib\/II study. Clin. Cancer Res. 27, 3061 (2021).","journal-title":"Clin. Cancer Res."},{"key":"30569_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer, E. P. et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 499\u2013511 (2021).","journal-title":"Lancet Oncol."},{"key":"30569_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar, W. J. et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc Netw. 18, 452\u2013478 (2020).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"30569_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623\u20131649 (2020).","journal-title":"Ann. Oncol."},{"key":"30569_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes, J. et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377, 914\u2013923 (2011).","journal-title":"Lancet"},{"key":"30569_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","volume":"112","author":"P Yuan","year":"2019","unstructured":"Yuan, P. et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur. J. Cancer 112, 57\u201365 (2019).","journal-title":"Eur. J. Cancer"},{"key":"30569_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4161\/15384047.2014.986973","volume":"16","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. Cancer Biol. Ther. 16, 225\u2013232 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"30569_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000136796","volume":"73","author":"D Laessig","year":"2007","unstructured":"Laessig, D. et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 73, 407\u2013414 (2007).","journal-title":"Oncology"},{"key":"30569_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"30569_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2179","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2179 (2019).","journal-title":"Clin. Cancer Res"},{"key":"30569_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000696","volume":"8","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J. Immunother. cancer 8, e000696 (2020).","journal-title":"J. Immunother. cancer"},{"key":"30569_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman, P. A. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 33, 594\u2013601 (2015).","journal-title":"J. Clin. Oncol."},{"key":"30569_CR17","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/cas.13392","volume":"108","author":"K Ito","year":"2017","unstructured":"Ito, K. et al. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. Cancer Sci. 108, 2273\u20132280 (2017).","journal-title":"Cancer Sci."},{"key":"30569_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","volume":"7","author":"E Zsiros","year":"2021","unstructured":"Zsiros, E. et al. Efficacy and safety of Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: A Phase 2 Nonrandomized clinical trial. JAMA Oncol. 7, 78\u201385 (2021).","journal-title":"JAMA Oncol."},{"key":"30569_CR19","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"30569_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-021-06128-4","volume":"186","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Cancer Res Treat. 186, 687\u2013697 (2021).","journal-title":"Breast Cancer Res Treat."},{"key":"30569_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO.2021.39.15_suppl.1006","volume":"39","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. J. Clin. Oncol. 39, 1006\u20131006 (2021).","journal-title":"J. Clin. Oncol."},{"key":"30569_CR22","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-18-3524","volume":"25","author":"Y Xiao","year":"2019","unstructured":"Xiao, Y. et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin. Cancer Res. 25, 5002\u20135014 (2019).","journal-title":"Clin. Cancer Res."},{"key":"30569_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.20892\/j.issn.2095-3941.2020.0418","volume":"18","author":"A Zhu","year":"2021","unstructured":"Zhu, A. et al. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. Cancer Biol. Med 18, 875\u2013887 (2021).","journal-title":"Cancer Biol. Med"},{"key":"30569_CR24","doi-asserted-by":"publisher","first-page":"GS1-04","DOI":"10.1158\/1538-7445.SABCS18-GS1-04","volume":"79","author":"L Emens","year":"2019","unstructured":"Emens, L. et al. Abstract GS1-04: IMpassion130: efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-na\u00efve, locally advanced or metastatic triple-negative breast cancer. Cancer Res. 79, GS1-04\u2013GS01-04 (2019).","journal-title":"Cancer Res."},{"key":"30569_CR25","doi-asserted-by":"publisher","unstructured":"Schmittnaegel, M. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aak9670 (2017).","DOI":"10.1126\/scitranslmed.aak9670"},{"key":"30569_CR26","doi-asserted-by":"publisher","unstructured":"Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aal3604 (2017).","DOI":"10.1126\/scitranslmed.aal3604"},{"key":"30569_CR27","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.20.01920","volume":"38","author":"C Lan","year":"2020","unstructured":"Lan, C. et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J. Clin. Oncol. 38, 4095\u20134106 (2020).","journal-title":"J. Clin. Oncol."},{"key":"30569_CR28","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/JCO.19.00318","volume":"37","author":"VE Maher","year":"2019","unstructured":"Maher, V. E. et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J. Clin. Oncol. 37, 2730\u20132737 (2019).","journal-title":"J. Clin. Oncol."},{"key":"30569_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"30569_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"30569_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41571-020-0338-6","volume":"17","author":"D Romero","year":"2020","unstructured":"Romero, D. B cells and TLSs facilitate a response to ICI. Nat. Rev. Clin. Oncol. 17, 195\u2013195 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"30569_CR32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"30569_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12595","volume":"7","author":"N Mart\u00edn-Mart\u00edn","year":"2016","unstructured":"Mart\u00edn-Mart\u00edn, N. et al. Stratification and therapeutic potential of PML in metastatic breast cancer. Nat. Commun. 7, 12595 (2016).","journal-title":"Nat. Commun."},{"key":"30569_CR34","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1172\/JCI89957","volume":"127","author":"YT Wang","year":"2017","unstructured":"Wang, Y. T. et al. Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment. J. Clin. Invest 127, 2982\u20132997 (2017).","journal-title":"J. Clin. Invest"},{"key":"30569_CR35","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41419-018-1186-5","volume":"9","author":"J-H Baek","year":"2018","unstructured":"Baek, J.-H. et al. PLOD3 promotes lung metastasis via regulation of STAT3. Cell Death Dis. 9, 1138 (2018).","journal-title":"Cell Death Dis."},{"key":"30569_CR36","doi-asserted-by":"publisher","first-page":"722807","DOI":"10.3389\/fimmu.2021.722807","volume":"12","author":"J Shi","year":"2021","unstructured":"Shi, J. et al. Integrated profiling identifies PLOD3 as a potential prognostic and immunotherapy relevant biomarker in colorectal cancer. Front Immunol. 12, 722807 (2021).","journal-title":"Front Immunol."},{"key":"30569_CR37","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond, M. E. et al. American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784\u20132795 (2010).","journal-title":"J. Clin. Oncol."},{"key":"30569_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","volume":"131","author":"AC Wolff","year":"2007","unstructured":"Wolff, A. C. et al. American society of clinical oncology\/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab Med 131, 18\u201343 (2007).","journal-title":"Arch. Pathol. Lab Med"},{"key":"30569_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-0154-2","volume":"6","author":"M Amgad","year":"2020","unstructured":"Amgad, M. et al. Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group. npj Breast Cancer 6, 16 (2020).","journal-title":"npj Breast Cancer"},{"key":"30569_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control Clin. Trials"},{"key":"30569_CR41","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res 47, D1211\u2013d1217 (2019).","journal-title":"Nucleic Acids Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30569-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:29:16Z","timestamp":1669292956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30569-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30569"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30569-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3011"}}